prothipendyl
Small moleculeexperimental
PROTHIPENDYL is a neuroleptic azaphenothiazine used to treat anxiety and agitation in psychotic syndromes. It also shows strong antihistamine and anti-emetic actions. — NCATS
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
1
Earliest trial started Jan 1, 2015 (NCT02374567)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Dopamine D2 receptorINHIBITOR
DRD2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)CCCN1c2ccccc2Sc2cccnc21- Mol. weight
- 285.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2111030 ↗
- NCATS5O6VWA87VA ↗
- ChEMBLCHEMBL2107124 ↗
Also known as
- dominal
- dominal
- dominal
- phrenotropin
- prothipendyl
- prothipendyl
- prothipendyl
- prothipendyl
- prothipendyl
- prothipendyl
- prothipendyl
- prothipendyl hcl
- prothipendyl hcl
- prothipendyl hcl
- prothipendyl hydrochloride
- prothipendyl hydrochloride
- prothipendyl hydrochloride
- prothipendyl hydrochloride
- prothipendyl hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02435095 | Phase 4 | May 1, 2015 | RWTH Aachen University |
| NCT02374567 | Phase 3 | Jan 1, 2015 | Gottfried Wilhelm Leibniz Universität Hannover |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 1 | 1 | 2015 |
| RWTH Aachen University | Academic/Hospital | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1